Physician profile
Alberto Alonso
NPI 1669621058
$6,807.51
in general payments reported to CMS, 2019-2025
32 companies · $947 in 2025
The $947 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $982 · 2021: $919 · 2022: $977 · 2023: $1,276 · 2024: $1,110 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,332.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,173.13 | 2019-2024 | Xarelto |
| Abbvie INC. | $640.33 | 2020-2025 | Linzess, Creon, Viberzi |
| Astrazeneca Pharmaceuticals LP | $538.25 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $512.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $442.98 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $429.75 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $367.95 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $265.99 | 2021-2023 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $262.76 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $259.21 | 2020-2023 | Verquvo, Belsomra |
| Pfizer INC. | $253.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $202.45 | 2019-2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $201.41 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.03 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.85 | 2019-2024 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $127.22 | 2024-2025 | Zenpep |
| Amgen INC. | $114.06 | 2023-2025 | Otezla, Repatha, Evenity |
| Sumitomo Pharma America, INC. | $87.56 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $84.92 | 2024-2025 | Rexulti |
| Ardelyx, INC. | $83.06 | 2024 | Ibsrela |
| Dexcom, INC. | $78.41 | 2022-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $48.05 | 2021-2023 | Gvoke Hypopen |
| Opko Pharmaceuticals, LLC | $38.74 | 2021-2024 | Rayaldee |
| Janssen Biotech, INC. | $33.67 | 2024 | Xarelto |
| Acadia Pharmaceuticals INC | $33.20 | 2023 | Nuplazid |
| Shield Therapeutics INC | $29.77 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $24.67 | 2020 | |
| Phathom Pharmaceuticals, INC. | $22.25 | 2024 | Voquezna |
| Sun Pharmaceutical Industries INC. | $21.96 | 2020 | |
| Exact Sciences Corporation | $21.06 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $21.06 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $20.86 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Alonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.